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Background. Due to the aging general population, deceased
donors ≥55 years will form an increasingly larger proportion of
the deceased kidney donor pool.
Methods. Using data from the United States Renal Data
System, we determined the change in graft survival between
1996 and 2000 among 32,557 recipients of donors aged <55
years and ≥55 years in univariate and multivariate survival
analyses. We identified donor risk factors for graft loss that
might influence the decision to accept or reject donors <55
and ≥55 years. The initial glomerular filtration rate established
6 months after transplantation (initial GFR), and the stabil-
ity of GFR in the first post-transplant year (GFR at 12 months
post-transplantation—GFR at six months post-transplantation)
were compared between recipients of donors <55 and ≥55 years
and the association of these factors with graft survival was
determined.
Results. In 2000, one-year graft survival in donors ≥55 years
was 86.7%. Between 1996 and 1999 the projected graft half
life improved from 11.4 to 14.5 years for recipients of donors
<55 years (P < 0.01); however, there was no improvement
for recipients of donors ≥55 years (8.2 to 9.2 year, P =
0.46). Among donor factors studied, only cold ischemic time
>24 hours identified recipients of donors ≥55 years at risk for
graft loss. Compared to recipients of donors <55 years, recip-
ients of donors ≥55 years established a lower initial GFR (42
vs. 56 mL/min/1.73m2, P < 0.0001), and had less stable GFR
in the first post-transplant year (−1.5 vs. −0.6 mL/min/1.73m2,
P <.0001). Recipients from donors ≥55 years with initial GFR
≥50 mL/min/1.73m2 and no drop GFR during the first post-
transplant year had graft survival that was superior to that of
donors <55 years with either initial GFR <50 mL/min/1.73m2
or a drop in GFR during the first post-transplant year.
Conclusion. Donors ≥55 years are a valuable resource. De-
spite improvements in immunosuppression, rejection, and de-
layed graft function, the projected increase in long-term graft
survival among recipients of donors <55 years was not shared
among recipients of donors ≥55 years. Recipients of donors ≥55
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years had lower initial GFR, and less stable GFR during the first
post-transplant year. Limiting cold ischemic time to <24 hours
may improve outcomes among recipients of donors ≥55 years.
Future studies to maximize initial GFR and minimize early loss
of GFR in recipients of donors ≥55 years may lead to improved
outcomes from deceased donors ≥55 years.
Despite the continued expansion of live donor pro-
grams, the demand for kidney transplantation still far
exceeds the supply of available organs [1, 2]. As a re-
sult, there is increasing need to consider the transplant of
organs from deceased donors of advanced age. In 1996,
donors aged ≥50 years accounted for 18.2% of all de-
ceased donor kidney transplants performed in the United
States compared to only 10.4% in 1988 [3]. In 1998, an
estimated 30% of deceased donors in Spain were over 60
years of age [4]. It is likely that deceased donors of ad-
vanced age will form an increasingly greater proportion
of the eligible donor pool in the future because of aging
in the general population and implementation of public
safety initiatives to decrease traumatic deaths.
Recipients of advanced age deceased donor kidney
transplants have inferior graft survival compared to recip-
ients of younger deceased donor kidney transplants [5, 6].
This has been attributed to a variety of reasons, including
reduced nephron mass, senescence, greater susceptibility
to ischemic reperfusion injury and, hence, increased inci-
dence of delayed graft function (DGF) and acute rejec-
tion [7–9]. In the current era of immunosuppression, the
relative importance of traditional barriers to long-term
kidney allograft survival, such as acute rejection, has de-
creased, while there have been relatively few advances in
organ procurement and preservation that could impact
the survival of organs from deceased donors of advanced
age.
The purpose of this study was to reexamine the impact
of donor age on long-term graft survival in the current era,
and to identify factors that limit the achievement of long-
term graft survival from deceased donors of advanced
age. The specific aims of this study were: (1) to com-
pare the improvement in graft survival during the years
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1996 to 2000 between recipients of deceased donor kid-
neys <55 years and ≥55 years; (2) to determine whether
donor factors (other than donor age) have a differen-
tial association with graft survival in recipients of de-
ceased donor kidneys <55 years and ≥55 years; (3) to
compare the level of initial allograft function [glomeru-
lar filtration rate (GFR) at six months post- transplan-
tation] and stability of allograft function in the first
post-transplant year (GFR at 12 months—GFR at six
months) between recipients of deceased donor kidneys
<55 years and ≥55 years; and (4) to compare the as-
sociation of initial allograft function and stability of al-
lograft function in the first post-transplant year with
graft survival in the recipients of deceased donor kidneys
<55 years and ≥55 years.
METHODS
Using data from the United States Renal Data Sys-
tem, we studied all adult (>18 years) deceased donor
kidney–only transplant recipients in the United States
from January 1, 1996 to December 31, 2000. Patients with
dual transplants (N = 338) were included in the study. Re-
cipients with missing information regarding donor age or
extreme donor preprocurement serum creatinine mea-
surements (>3.5 mg/dL or <0.5 mg/dL) were excluded.
Patients were followed until graft loss (due to death,
dialysis, or repeat transplantation) or end of follow-up,
December 31, 2000.
Graft failure rates per 100 patient years were de-
termined by donor age. Based on these results, trans-
plant recipients were divided into two groups, those with
donors <55 years and ≥55 years. Identical parallel anal-
yses were performed in these two donor age groups.
Donor, recipient, and transplant characteristics were de-
scribed as the mean and standard deviation for contin-
uous variables and frequency for categorical variables,
unless otherwise indicated. Transplant characteristics in-
cluded delayed graft function (DGF), defined by the need
for dialysis in the first week following transplantation, and
clinical acute rejection (AR), defined by the administra-
tion of immunosuppressive medications for the treatment
of acute rejection in the first six months following trans-
plantation. Changes in donor, recipient, and transplant
characteristics during the study period were determined
by transplant year.
The Kaplan-Meier method was used to estimate the
graft survival by transplant year. The association of
transplant year with long-term graft survival was de-
termined among those patients with graft survival of
at least 12 months in parametric multivariate time to
event analyses. Recipient age, gender, race, and dia-
betes as the cause of end-stage renal disease (ESRD),
as well as donor race and gender, were chosen a pri-
ori to be included in these multivariate models. Addi-
tional variables were included based on their associa-
tion with graft survival in Kaplan-Meier analyses. The
final models in recipients of donors <55 years and ≥55
years included the following uniform set of covariates:
recipient age, gender, race, cause of ESRD, history of
previous kidney transplantation, pretransplant panel re-
active antibody level (>20%), degree of HLA mismatch,
donor race, donor gender, donor mechanism of death
due to cerebrovascular accident (CVA), donor history
of hypertension, donor preprocurement serum creatinine
>1.5 mg/dL, cold ischemia time (CIT) >24 hours, DGF,
AR, use of induction therapy at time of transplantation
(interleukin-2 receptor antagonists, polyclonal and mon-
oclonal depleting antibody therapy), and type of main-
tenance immunosuppression at time of discharge from
hospital following transplant surgery (Neoral, Sandim-
mune, tacrolimus, mycophenolate mofetil, azathioprine,
and prednisone). No attempt to impute missing data was
made. For patients with missing values for categorical
variables, a category of unknown was created, and these
patients were included in the multivariate models. Graft
half-life was projected assuming both exponential and
Weibull distributions for graft failures times [10]. Graph-
ical comparisons of the parametric hazard curves with the
empiric hazards were made, and the Weibull distribution
was used because it more closely approximated the em-
piric hazards. Preliminary models did not demonstrate an
independent association of donor age with patient sur-
vival (date not shown), and therefore, only the results for
graft survival (including death as a cause of graft loss) are
presented.
To determine whether donor factors had a differential
association with graft survival in recipients of deceased
donor kidneys <55 years and ≥55 years, the hazard ra-
tios for selected donor factors from parallel Cox regres-
sion analyses that included the same donor, recipient, and
transplant related factors were compared.
The GFR at six months after transplantation was de-
termined by transplant year using an equation derived
from the MDRD study [abstract; Levey et al, J Am Soc
Nephrol 11:155, 2000]. Among patients with graft sur-
vival of at least one year, the stability of graft func-
tion in the first transplant year was determined as the
change in the estimated GFR between six and 12 months
post-transplantation (GFR at 12 months—GFR at six
months) (mL/min/1.73m2). The association of the ini-
tial allograft function at six months after transplantation,
and the stability of allograft function in the first post-
transplant year (drop in GFR between six and 12 months
post-transplantation ≥ 0 mL/min/1.73m2) was then de-
termined in a Kaplan-Meier analysis among patients with
graft survival of at least one year in each donor age group.
All analyses were performed by SAS statistical software,
Woo et al: Kidney allograft survival in older cadaveric donors 2409
0
5
10
15
20
G
ra
ft 
fa
ilu
re
 ra
te
,
pe
r 1
00
 p
at
ie
nt
 y
ea
rs
20 30 40 50 60 70
Donor age
Fig. 1. Point estimate and 95% CI of graft failure rates per 100 patient
years by donor age. Donor age was divided into three-year intervals
between the ages of 16 and 73 years. Because of the small number of
donors, a single graft failure rate was determined for donors <16 years
and >73 years.
version 8.1 (SAS Institute, Cary, NC, USA). The study
received local ethics review board approval.
RESULTS
There were 37,003 adult kidney-only transplant recip-
ients between 1996 and 2000. We excluded 1521 patients
with missing donor age and 2925 patients with extreme
donor preprocurement serum creatinine values. The char-
acteristics of the excluded patients were similar to those
of study patients (data not shown). Figure 1 shows the
graft failure rates per 100 patient years by donor age. Al-
though there were some increases in graft failure rates
with donor age greater than 40 years, graft failure rates
remained relatively similar in the range of 5 to 10 per
100 patient years. There was a larger increase in graft
failure rates after the donor age of 55 years, and graft
failure rates were consistently above 10 per 100 patient
years when donors were > age of 60 years.
The characteristics of the 32,557 study patients grouped
by donor age are shown in Table 1. Approximately 15%
of deceased donor transplants during each year under
study (1996–2000) were from donors aged ≥55 years.
Within donor age groups, the recipient characteristics
remained similar between 1996 and 2000 except for in-
creased transplantation of patients with diabetes. Table 2
shows the donor- and transplant-related characteristics.
Within donor age groups, the majority of the donor and
transplant characteristics also remained constant during
the study period. However, there was a significant change
in the use of immunosuppressant medications between
1996 and 2000, and a significant reduction in percentage
of kidneys with CIT >24 hours in both donor age groups
(Table 2).
Figure 2 shows the Kaplan-Meier estimates of graft sur-
vival by transplant year. There was a trend toward an im-
provement in long-term graft survival among recipients
of donors <55 years (P = 0.06), but not among recipients
of donors ≥55 years. For recipients of donor <55 years,
one-year graft survival improved from 92.5% in 1996 to
93.4% in 2000, P = 0.07 (log-rank test). For recipients of
donors ≥55 years, one-year graft survival showed a sim-
ilar small improvement between 1996 (85.9%) and 2000
(86.7%), P = 0.40 (log-rank test).
The incidence of AR and DGF, as well as the mean esti-
mated GFR at six months’ post-transplant and the change
in GFR between six and 12 months’ post-transplantation
by transplant year are shown in Table 3. The overall inci-
dence of AR was higher in recipients of donors ≥55 years.
The AR rates significantly decreased in both donor age
groups during the study period. The overall incidence of
DGF was higher in recipients of donors ≥55 years. There
was a significant drop in DGF during the study period
in both donor groups. The overall mean estimated GFR
at six months post-transplant was significantly higher in
recipients of donors <55 years. There was no clinically
significant change in the GFR established at six months
after transplantation during the study period in either
donor age group. Recipients of donors ≥55 years had a
significantly larger decrease in the GFR between six and
12 months post-transplantation compared to recipients
of donors <55 years. There was no clinically significant
change in the stability of GFR during the first post-
transplant year during the study period in either donor
age group.
Figure 3 shows the survival estimates by transplant
year from the multivariate time to event analyses in
patients with graft survival of at least one year. There
was a statistically significant improvement in graft sur-
vival among recipients of donors <55 years only. The
improvement in graft survival over time is quantified in
Figure 4, which shows a significant improvement in graft
half-life over time in recipients of donors <55 years but
not ≥55 years.
Table 4 shows the results of the parallel Cox regression
analyses performed to compare the strength of the associ-
ation of selected donor factors with graft survival in recip-
ients of donor kidneys <55 years and ≥55 years. These
analyses were performed to identify donor factors that
may influence the decision to accept an organ for trans-
plantation within each donor age group. Among donors
aged ≥55, only prolonged CIT >24 hours was associ-
ated with an increased risk of graft loss. Among donors
<55 years, donor death from CVA and HLA mismatch
>4 were significant risk factors for graft loss. However,
donor history of hypertension, donor preprocurement
serum creatinine >1.5 mg/dL, and CIT >24 hours were
not associated with increased risk of graft loss.
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Table 1. Recipient characteristics by donor age group and transplant year
1996 1997 1998 1999 2000
Donor age <55 years
Number of transplants 5,374 5,332 5,594 5,644 5,534
Age (years, mean ± SD) 46 ± 12 46 ± 12 46 ± 12 46 ± 12 46 ± 12
Gender (% male) 60.6 61.2 61.1 60.4 61.1
Race%
White 65.1 63.7 65.6 65.3 65.8
Black 28.6 29.7 28.2 28.4 27.9
Other 6.3 6.6 6.2 6.3 6.3
First transplants% 86.5 85.6 85.9 86.8 86.1
Primary renal disease%
Diabetes mellitus 22.2 22.7 23.1 27.3 30.0
Glomerular disease 29.6 29.5 30.5 28.2 26.8
Other 48.2 47.8 46.4 44.5 43.2
Panel reactive antibody%
Current >20% 11.1 11.6 10.8 11.4 11.0
Peak >20% 22.3 22.5 20.6 21.6 21.1
Donor age ≥55 years
Number of transplants 976 1,002 1,081 1,033 987
Age (years, mean ± SD) 49 ± 12 51 ± 11 51 ± 11 52 ± 12 52 ± 12
Gender (% male) 60.4 58.7 58.8 60.7 57.1
Race (%)
White 61.4 64.9 61.1 60.8 60.8
Black 31.8 28.9 29.4 30.9 31.5
Other 6.8 6.1 9.5 8.3 7.7
First transplants% 87.9 90.1 89.1 90.2 87.1
Primary renal disease%
Diabetes mellitus 23.7 25.2 26.3 28.0 27.4
Glomerular disease 24.8 24.9 24.9 24.2 26.9
Other 51.5 49.9 48.8 47.8 45.7
Panel reactive antibody%
Current >20% 9.3 9.2 8.2 8.0 11.3
Peak >20% 20.9 19.6 19.6 16.7 21.3
Figure 5 shows that recipients from donors ≥55 years
who achieved both an initial GFR at six months
≥50 mL/min/1.73m2, and had stable GFR between
six and 12 months post-transplantation (loss of GFR
≥0 mL/min/1.73m2) had graft survival that was compa-
rable to that of recipients of donors <55 years, with
similar initial GFR and stability of GFR in the first post-
transplant year, and higher graft survival than recipients
in either donor age group who did not achieve these levels
of initial allograft function and stability.
DISCUSSION
Our study confirms that excellent short-term and an-
ticipated long-term outcomes can be achieved with de-
ceased donor organs ≥55 years. Despite these excellent
outcomes, we found that there has been no increase
in transplantation from deceased donors ≥55 years be-
tween 1996 and 2000. In contrast to recent reports, [11]
we found a projected increase in graft survival among
donors <55 years but not among donors ≥55 years, sug-
gesting that projections of graft survival should be consid-
ered separately among deceased donors in different age
groups. Among donors ≥55 years, the only donor factor
available to clinicians prior to transplantation that was
predictive of transplant outcome was cold ischemic time
>24 hours. In order to identify potentially modifiable fac-
tors that may lead to long-term improvements in graft sur-
vival, we determined the association of initial allograft
function (GFR at six months post-transplantation) and
stability of allograft function in the first post-transplant
year (drop in GFR between six and 12 months post-
transplantation) with graft survival. Both the initial GFR
at six months after transplantation and the stability of
GFR in the first transplant year were significantly lower
among recipients of donors ≥55 years. These factors were
associated with long-term graft survival, and patients who
achieved an initial GFR ≥50 mL/min/1.73m2 and had no
loss of GFR in the first post-transplant year had the high-
est graft survival irrespective of the donor age group.
These findings suggest that strategies to improve both
the initial level and stability of allograft function in the
first post-transplant year may lead to long-term improve-
ments in graft survival in recipients of donors ≥55 years
of age.
Our findings support the expanded use of deceased
donors ≥55 years. We found the one-year graft survival
from donors ≥55 years in the current era (86%-88%) to
be higher than that reported in previous years. For the
transplant years 1988 to 1994, Hariharan et al reported
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Table 2. Donor and transplant characteristics by donor age group and transplant year
Donor Age < 55 years
Donor age (mean ± SD) 32 ± 14 32 ± 14 32 ± 14 32 ± 14 32 ± 14
Donor gender (% male) 62.9 64.0 61.8 61.7 63.4
Donor race%
White 85.5 84.7 85.9 86.6 86.2
Black 12.1 12.5 11.7 10.9 11.2
Other 2.4 2.8 2.4 2.5 2.6
Donor cause of death (% cerebrovascular accident) 33.5 32.1 34.7 32.7 31.8
Donor history of hypertension% 14.1 14.1 16.3 15.7 13.2
Donor preprocurement creatinine mg/dL (mean ± SD) 1.04 ± 0.43 1.04 ± 0.43 1.04 ± 0.43 1.03 ± 0.43 1.03 ± 0.41
HLA mismatch (mean ± SD) 3.1 ± 1.8 3.2 ± 1.8 3.2 ± 1.8 3.3 ± 1.8 3.4 ± 1.9
Cold ischemia time
Mean ± SD 21.1 ± 8.3 20.3 ± 8.1 20.3 ± 8.3 19.3 ± 8.4 18.6 ± 8.4
% >24 hours 36.2 32.4 32.1 29.1 26.6
Induction therapy%
IL-2 receptor antagonist 1.0 0.2 11.9 31.7 40.7
Monoclonal/polyclonal antibody 46.3 42.7 27.6 19.5 21.2
Immunosuppression%
Neoral 57.1 68.3 62.4 50.4 41.1
Sandimmune 9.7 6.3 4.2 4.6 2.1
Tacrolimus 14.0 20.3 26.8 35.7 46.1
MMF 51.0 70.3 75.6 78.6 74.9
Azathioprine 30.6 18.6 10.2 6.5 4.5
Prednisone 93.3 93.8 92.7 90.7 89.8
Donor age ≥55 years
Donor age (mean ± SD) 61.5 ± 5.0 61.8 ± 5.3 61.8 ± 5.3 61.4 ± 5.1 60.9 ± 4.7
Donor gender (% male) 45.6 49.1 45.7 48.2 49.3
Donor race%
White 92.4 91.2 91.9 88.9 90.8
Black 5.9 7.4 5.5 6.7 5.9
Other 1.7 1.4 2.6 4.4 3.3
Donor cause of death (% cerebrovascular accident) 78.3 77.5 80.9 77.4 75.4
Donor history of hypertension% 43.1 49.6 43.4 45.1 43.2
Donor preprocurement creatinine mg/dL (mean ± SD) 1.06 ± 0.39 1.02 ± 0.36 1.03 ± 0.40 1.04 ± 0.41 1.03 ± 0.36
HLA mismatch (mean ± SD) 3.2 ± 1.7 3.3 ± 1.8 3.4 ± 1.7 3.3 ± 1.7 3.3 ± 1.8
Cold ischemic time
Mean ± SD 22.4 ± 8.5 21.2 ± 8.0 21.5 ± 8.4 21.2 ± 8.3 20.1 ± 8.3
% >24 hours 42.4 34.9 38.3 37.7 32.4
Induction therapy%
IL-2 receptor antagonist 0.6 0 12.0 29.2 38.5
Monoclonal/polyclonal antibody 50.1 44.6 33.6 21.1 22.3
Immunosuppressiona%
Neoral 52.8 68.4 58.9 49.8 40.7
Sandimmune 12.1 6.3 3.9 5.7 1.9
Tacrolimus 15.5 19.8 28.6 33.8 42.1
MMF 55.7 70.6 75.7 79.6 73.9
Azathioprine 26.5 17.6 11.8 5.7 3.1
Prednisone 92.5 94.5 93.0 92.0 85.5
aAt time of discharge from hospital after transplant surgery.
one-year graft survival of 77.3% for donor kidneys aged
51 to 60, and 71.7% for donor kidneys aged >60 years
[12]. The one-year graft survival from deceased donors
≥55 years in the current era exceeds the 87% one-year
graft survival that was achieved for deceased donor re-
cipients aged 19 to 50 years in the United States in 1994.
However, we did not find increased utilization of de-
ceased donors ≥55 years between 1996 and 2000. This
represents a change from 1988 to 1996, when transplan-
tation from deceased donors >50 years increased from
10.4% to 18.2% [3]. Similarly, Kasiske et al reported that
the progressive increase in transplantation from deceased
donors ≥55 years between 1988 and 1995 did not continue
in 1996 [13]. The Kidney Work Group report of the Crys-
tal City meeting reported a discard rate of more than 15%
for all kidneys recovered for transplantation [14], and this
rate approaches 50% for kidneys recovered from donors
over age 60. Our findings suggest reluctance in the trans-
plant community to accept advanced age donors, and the
need for increased awareness of the anticipated outcomes
from advanced age deceased donors.
We sought to determine whether donor factors rou-
tinely available to clinicians prior to transplantation could
be used to identify organs at increased risk of graft fail-
ure among donors ≥55 years. Therefore, our approach
differs from that used to define expanded criteria donors,
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Fig. 2. Kaplan-Meier estimates of graft
survival in recipients of donors<55 years and
≥55 years by transplant year. The P value
was generated from the log-rank test for the
comparison of survival in the years 1996 and
2000.
Table 3. Acute rejection, delayed graft function, glomerular filtration rate (GFR), and stability of allograft function in the first post-transplant
year by donor age group
Donors <55 years
Overall Mean 1996 1997 1998 1999 2000 Pa
Acute rejection% 9.8 12.6 11.1 10.1 8.1 7.1 <.0001
Delayed graft function% 21.4 22.9 21.8 22.0 21.3 19.0 <.0001
GFR at six months mL/min/1.73m2 56 ± 0.1 54 ± 0.3 57 ± 0.3 56 ± 0.3 57 ± 0.3 57 ± 0.4 <.0001
Stability of GFR in first post-transplant yearbmL/min/1.73m2 −0.6 ± 0.1 2.1 ± 0.2 −3.0 ± 0.2 −0.9 ± 0.2 −0.8 ± 0.2 −0.3 ± 0.3 <.0001
Donors ≥55 years
Acute rejection% 11.2 15.5 11.2 10.8 10.7 7.8 <.0001
Delayed graft function% 32.9 37.1 32.7 34.5 32.2 27.7 <.0001
Mean GFR at six months mL/min/1.73m2 42 ± 0.3 40 ± 0.6 42 ± 0.6 42 ± 0.5 42 ± 0.5 44 ± 0.8 <.0001
Stability of GFR in first post-transplant yearb −1.5 ± 0.2 0.9 ± 0.5 −3.4 ± 0.5 −2.1 ± 0.4 −0.9 ± 0.4 −1.8 ± 0.5 <.0001
aP value for change during the study period 1996 to 2000.
bGFR at 12 months—GFR at 6 months post-transplantation.
which focused on identifying factors associated with an
increased risk of graft loss compared to ideal donors [15].
Consistent with other recent reports [16], we identified
prolonged cold ischemic time to be associated with in-
creased risk of graft failure among donors ≥55 years.
Prolonged exposure to cold ischemia should be partic-
ularly avoided among these donors. Donor mechanism
of death, donor hypertension, and donor serum creati-
nine >1.5 mg/dL were not predictive of graft survival,
and should not be used to exclude donors ≥55 years.
These findings are consistent with the Organ Procure-
ment and Transplantation Network (OPTN) approved
definition of an expanded criteria donor (ECD), which
categorizes donor risk primarily on the basis of donor age
>60 years [17]. It is important to note that other factors
not available for analysis in our study, such as pretrans-
plant biopsy findings, may be useful in deciding whether
to proceed with transplantation from an advanced aged
deceased donor.
Of concern was the finding that advances in immuno-
suppression, acute rejection, and cold ischemic time in
the current era have led to a projected increase in graft
survival from donors <55 years but not among donors
≥55 years. Overall, these findings indicate the need for fu-
ture research initiatives to identify modifiable factors that
impact graft survival from donors ≥55 years. We identi-
fied two such potential factors, the initial level of allograft
function achieved after transplantation, and the stability
of allograft function in the first post-transplant year. We
found that recipients of donors in either age group with an
initial GFR >50 mL/min/1.73m2 and stability of allograft
function in the first post-transplant year (change in GFR
between six and 12 months ≥0 mL/min/1.73m2) had the
highest survival, and that these factors seemed to negate
the importance of donor age. Unfortunately, few recipi-
ents from donors ≥55 years had both a high level of ini-
tial GFR and stability of GFR in the first post-transplant
year. The change in GFR between six and 12 months
Woo et al: Kidney allograft survival in older cadaveric donors 2413
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Fig. 4. Projected graft half-life in recipients of cadaveric donors <55
years and ≥55 years. Between 1996 and 1999, there was a significant
improvement in projected graft half-life in recipients of donors <55
years but not in recipients of donors ≥55 years.
post-transplant has recently been shown to be indepen-
dently associated with long-term allograft survival [ab-
stract; Siddiqi et al, Am J Transplant 4(Suppl 8):S473,
2004]. The degree to which the initial level of allograft
function and stability of allograft function are determined
by donor as opposed to post-transplant factors warrants
further study. Recently, the initial level of allograft func-
tion but not the stability of allograft function was found to
be associated with donor source [abstract; Gourishankar
et al, Am J Transplant 4(Suppl 8):S476, 2004], suggest-
ing that factors arising after transplantation (which may
be modifiable) determine the initial stability of allograft
function.
Our analysis of the USRDS database provided an op-
portunity to study a large sample of transplant recipients,
but is subject to a number well-known limitations inher-
ent to a retrospective analysis of a national database that
should be considered when interpreting results of our
study. Every attempt was made to include missing data
in our analyses, and we found no evidence of nonran-
dom missing data between the donor age groups. Our
donor age grouping of <55 years and ≥55 years were
chosen based on the observed graft failure rates shown
in Figure 1. Although our donor age categories are some-
what arbitrary, they are consistent with previous publi-
cations regarding this topic [13, 14]. The projections of
allograft survival reported in this study were based on an
assumed distributional form for the graft survival times.
The validity of the assumed distibutional form can only
be checked for the range of survival times in the data
set and, therefore, projections beyond the range of the
data should be interpreted with caution. In these analyses,
information regarding maintenance immunosuppression
was based on the medications recorded at time of dis-
charge from hospital following transplant surgery and,
therefore, changes in immunosuppression after discharge
are not captured in this analysis.
CONCLUSION
Our analysis demonstrates the excellent short-term
and acceptable projected long-term graft survival with
donors ≥55 years. These results should help overcome the
reluctance to utilize such donors suggested in this analy-
sis. The improvements in immunosuppression, rejection,
and delayed graft function in the current era have not
improved outcomes in donors ≥55 years, suggesting the
need for alternative strategies in this donor group. Initial
allograft function and early stability of allograft function
appear to be important. Future studies to maximize ini-
tial allograft function and minimize early loss of allograft
function should be pursued.
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Table 4. Donor factors and risk of graft loss among donors <55 years and ≥55 yearsa
Donor age <55 years Donor age ≥55 years
Hazard ratio 95% CI Hazard ratio 95% CI
Cold ischemia time >24 hours 0.93 0.84–1.03 1.20 1.01–1.43
HLA mismatch ≥4 1.34 1.15–1.55 1.11 0.82–1.49
Donor death by CVA 1.27 1.14–1.40 1.05 0.85–1.30
Donor history of hypertension 1.09 0.96–1.24 1.03 0.87–1.22
Donor creatinine >1.5 mg/dL 1.06 0.92–1.22 1.22 0.93–1.60
a Hazard ratios from separate but identical Cox regression models in donors <55 years and ≥55 years. The multivariate models included the following additional
factors: recipient age, gender, race, cause of end-stage renal disease, history of previous kidney transplantation, pretransplant panel reactive antibody level (>20%),
donor race, gender, delayed graft function, acute rejection, use of induction therapy at time of transplant (interleukin-2 receptor antagonists, polyclonal and monoclonal
depleting antibody therapy), and type of maintenance immunosuppression at time of discharge from hospital following transplant surgery (Neoral, Sandimmune,
tacrolimus, mycophenolate mofetil, azathioprine, and prednisone).
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Fig. 5. Kaplan-Meier survival estimates of
recipients grouped according to donor age,
initial glomerular filtration rate (GFR) estab-
lished at six months after transplantation, and
the change in GFR between six and 12 months
after transplantation (delta GFR). Recipients
of donors ≥55 years are shown in bold. Recip-
ients who achieved both an initial GFR ≥50
mL/min/1.73m2 and had no loss of GFR be-
tween six and 12 months post-transplantation
are shown with dotted lines. The N = 5755
recipients of donors <55 years and N = 323
recipients ≥55 years who achieved both an ini-
tial GFR ≥50 mL/min/1.73m2 and had no loss
of GFR had comparable graft survival that
was higher than that among N = 12,283 recip-
ients of donor <55 years or N = 2738 recipi-
ents of donors ≥55 years who did not achieve
the same level of initial GFR or GFR stabil-
ity. The analysis includes only patients who
had GFR estimates at six and 12 months after
transplantation.
The data reported here have been supplied by the United States Renal
Data System (USRDS). The interpretation and reporting of these data
are the responsibility of the authors, and in no way should be seen as
an official policy or interpretation of the United States government.
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